Adenosine, lidocaone, and magnasium cocktail in massive transfusion patients

Evaluating the safety of Administration of Adenosine, Lidocaine, and Mg(ALM) cocktail among Multiple Trauma Patients receiving Massive Transfusion with dose escalation A phase I, clinical trial

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230707058707N1

Enrollment

Registered

2023-12-06

Start date

2023-12-22

Completion date

Unknown

Last updated

2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

repairfusion injury.

Interventions

Intervention 1: 1st Intervention group: Adenosine lidocaine magnesium combination will be given to 4 eligible patients simultaneously with the second blood bag in two doses of bolus and infusion. If t

Eligibility

Sex/Gender

All

Age

16 Years to 60 Years

Inclusion criteria

Inclusion criteria: Candidate to recieve the second pack of packed red blood cell A candidate to receive the first bag of red blood cells who has a systolic pressure of 80 or lower

Exclusion criteria

Exclusion criteria: Severe underlying disease specially cardiac, renal, and pulmonary Paitient with slash thoracotomy Penetrating brain injury or exposed brain matter Paitients with irregular base electrocardiogram

Design outcomes

Primary

Measure	Time frame
Mortality. Timepoint: during hospital admission. Method of measurement: number of mortality in admited paitients.;Recovery from trauma. Timepoint: At time of discharge from hospital. Method of measurement: duration of hospital admission.;Amount of recieved blood. Timepoint: At the end of hospital admission. Method of measurement: amount of recieved pack cell.;Amount of hemoglubin rise. Timepoint: before bolus after bolus and after drip. Method of measurement: cheking blood hemoglubin.;Renal function. Timepoint: before bolus after bolus and after drip. Method of measurement: checking BUN and Cr.;Improvement of clinical course. Timepoint: before bolus after bolus and after drip. Method of measurement: arterial blood gas.;Severity of hemolysis. Timepoint: before bolus after bolus and after drip. Method of measurement: checking blood lactate dehydrogenase.;Coagulopathy recovery. Timepoint: before bolus after bolus and after drip. Method of measurement: prothrombin time(PT), partial trombopalstin time(PTT), international normalized ratio(INR).	—

Measure

Time frame

Mortality. Timepoint: during hospital admission. Method of measurement: number of mortality in admited paitients.;Recovery from trauma. Timepoint: At time of discharge from hospital. Method of measurement: duration of hospital admission.;Amount of recieved blood. Timepoint: At the end of hospital admission. Method of measurement: amount of recieved pack cell.;Amount of hemoglubin rise. Timepoint: before bolus after bolus and after drip. Method of measurement: cheking blood hemoglubin.;Renal function. Timepoint: before bolus after bolus and after drip. Method of measurement: checking BUN and Cr.;Improvement of clinical course. Timepoint: before bolus after bolus and after drip. Method of measurement: arterial blood gas.;Severity of hemolysis. Timepoint: before bolus after bolus and after drip. Method of measurement: checking blood lactate dehydrogenase.;Coagulopathy recovery. Timepoint: before bolus after bolus and after drip. Method of measurement: prothrombin time(PT), partial trombopalstin time(PTT), international normalized ratio(INR).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyed Soheil Sahafi

Shiraz University of Medical Sciences

soheilsahafi515@gmail.com+98 71 3656 1547

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026